Key result
Sitagliptin decreased hsCRP and ADP or AA-induced platelet aggregation rate compared with metformin in T2DM patients with aspirin resistance.
Why the study?
Does sitagliptin improve aspirin resistance in patients with Type 2 diabetes mellitus?
Cohort (n=68)
Does sitagliptin improve aspirin resistance in patients with Type 2 diabetes mellitus?
Sitagliptin significantly improves aspirin resistance and oxidative stress inflammatory state in T2DM patients independently of blood glucose control.
Answers are grounded in this paper and cite their sources.
May reduce aspirin resistance in T2DM beyond glycemic effects; hypothesis-generating, requiring larger confirmatory trials.
OBJECTIVE: To explore the impact of sitagliptin on aspirin resistance (AR) in patients with Type 2 diabetes mellitus (T2DM). METHODS: A total of 68 cases of AR were chosen from 136 cases of T2DM patients. The clinical data, including blood samples, fasting plasma glucose (FPG), glycosylated hemoglobin (HbAlc), and high sensitive C reactive protein (hs-CRP) were collected. Aenosine diphosphate (ADP) and arachidonic acid (AA) -induced platelet aggregation rate (PAG) were detected in 1, 3, 6 and 12 months after the treatment to evaluate the impact of sitagliptin on AR. RESULTS: After 6 months of hypoglycemic treatment, FPG and HbAlc in two groups were at the normal level. The hypoglycemic effect was not obviously different (P>0.05), but the hsCRP and ADP or AA-induced PAG were decreased in the sitagliptin group with statistical significance when compared with the metformin group (P<0.05). CONCLUSION: Sitagliptin can significantly improve the oxidative stress inflammatory state in T2DM patients and AR, which is independent on blood glucose control.
No takes yet. Share an insight, caveat, or question.
Li et al. (2015) conducted a cohort in Type 2 diabetes mellitus with aspirin resistance (n=68). Sitagliptin vs. Metformin was evaluated on hsCRP and ADP or AA-induced platelet aggregation rate (PAG) (p=<0.05). Sitagliptin decreased hsCRP and ADP or AA-induced platelet aggregation rate compared with metformin in T2DM patients with aspirin resistance.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: